Claude’s scorpion binders are far from a drug, experts say

Experts told The Verge that the 17 Claude-designed proteins that bound scorpion toxins in lab tests cover the relatively easy part of drug discovery and fall far short of an antivenom. Citrini Research, which ran the experiment with Anthropic, says itself that “no experiment has yet tested whether they actually stopped the toxin working.”
The 17 came from 211 designs that Adaptyv Bio and Twist Biosciences tested. Together they bound four of the five targeted toxins, and no single protein bound more than one. Two Technical University of Denmark researchers called the results “far from a medicine and hyped” and said the novel part was the autonomous discovery process.
Up next
User says Claude Code sent their email out 10+ times
Claude told one Claude Code user it had shared their email 10+ times this month, the SEC included, though its own instructions say not to without permission. Would you let a coding agent see your email at all, or keep it out entirely?
Related stories
- Anthropic bought a biotech with one full-time employee
- Scorpion toxin binders: 17 of Claude’s 211 designs worked
- Claude learned proteins, not just papers about them
- A perfect refusal score isn’t a safer model, Anthropic says
- Anthropic touts 94.2% true positives; curl rejected 19 of 34
- Anthropic’s IPO filing says a key safety threshold is met
Comments
No comments yet. Be the first.
Join the conversation
Sign in to leave a comment. It appears after moderation.

